Vanholder R, Van Biesen W, Nagler E V
a Nephrology Section, Department of Internal Medicine , University Hospital Ghent , Belgium.
Acta Clin Belg. 2019 Aug;74(4):215-228. doi: 10.1080/17843286.2018.1531206. Epub 2018 Oct 24.
In this publication, we review the definitions, symptoms, causes, differential diagnoses and therapies of hypokalemia and hyperkalemia.
Comprehensive tables and diagnostic algorithms are provided when appropriate.
Although both hypokalemia and hyperkalemia may be life-threatening, this is essentially the case with severe changes (serum potassium < 2.5 or > 6.5 mmol/L), the presence of symptoms or electrocardiographic deviations, the association with aggravating factors (e.g. digitalis intake) and/or rapid acute changes. Only these truly need an emergency therapeutic approach. In all other cases, a careful consideration of the causes and their correction should prevail over additional approaches to modify serum potassium concentration. Although most therapeutic approaches to both hypokalemia and hyperkalemia have been well established since many years, recently two new intestinal potassium binders have been introduced on the market. It remains to be elucidated whether these drugs truly have an additional role on top of the existing treatments.
在本出版物中,我们回顾低钾血症和高钾血症的定义、症状、病因、鉴别诊断及治疗方法。
在适当的时候提供综合表格和诊断算法。
尽管低钾血症和高钾血症均可能危及生命,但本质上只有在严重变化(血清钾<2.5或>6.5 mmol/L)、出现症状或心电图异常、伴有加重因素(如服用洋地黄)和/或快速急性变化时才会如此。只有这些情况真正需要紧急治疗方法。在所有其他情况下,仔细考虑病因并加以纠正应优先于其他改变血清钾浓度的方法。尽管多年来针对低钾血症和高钾血症的大多数治疗方法已得到充分确立,但最近有两种新型肠道钾结合剂已投放市场。这些药物在现有治疗之外是否真的具有额外作用仍有待阐明。